AIkido Pharma Inc. Appoints New Director, Soo Yu

Rhea-AI Summary

AIkido Pharma Inc. (NASDAQ: AIKI) announced the appointment of Soo Yu as a new director on June 10, 2022. This move comes in response to shareholder concerns about the company’s compliance with NASDAQ's diversity rules. CEO Anthony Hayes emphasized Yu's exemplary qualifications and the diverse expertise she brings, which aims to enhance the company's growth strategy. With a robust background in international finance, particularly in Asian markets, Ms. Yu's involvement could potentially open new avenues for AIkido's business development.

Positive

• Appointment of Soo Yu enhances board diversity and compliance with NASDAQ diversity rules.
• Soo Yu brings extensive international business development experience, potentially expanding growth opportunities.
• Yu's background in Asian markets could enhance AIkido's global reach and partnerships.

Negative

• Appointment may indicate prior governance concerns raised by shareholders regarding diversity compliance.
• Potential experience gaps if board dynamics shift significantly with new appointments.

New Director Supports NASDAQ Rule on Diversity

NEW YORK, June 10, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced the appointment of Ms. Soo Yu, as a director of the Company. 

Anthony Hayes, CEO of AIkido stated, "At the time of the annual meeting, there was concern expressed by some shareholders about the Company's compliance with the new NASDAQ rules on diversity.  The Company strongly believes in diversity and Ms. Yu is an exceptional candidate that also satisfies the new NASDAQ rule.  Further, Ms. Yu's background broadens the experience and expertise of the Company, as we seek new areas of growth and opportunity for the Company.  We welcome Ms. Yu and look forward to her involvement."

About Soo Yu

Soo Yu is the Managing Director of International Private Client Services for Revere Securities. With more than a decade of experience working in financial services, she focuses on international business development and the cultivation of overseas client banking relationships. A naturalized U.S. citizen originally from South Korea, Soo brings significant expertise in Asian markets and expansive global reach through her connectivity with international contacts.

Soo earned her B.A. in Fine Arts from the Fashion Institute of Technology and studied at the University of Nottingham and the Paris Fashion Institute. She holds Series 7 and Series 66 designations and her real estate license. Previously, she maintained her Series 79 and 24 licenses.

Soo actively supports several nonprofit organizations, including philanthropies committed to improving the lives of children and the elderly as well as sustainability.

Further information about Ms. Yu's appointment to the Board are provided in the Company's Form 8-K which was filed on June 10, 2022 with the Securities and Exchange Commission.

About AIkido Pharma Inc.

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics. The Company's platform consists of patented technology from leading universities and researchers, and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations: 

Hayden IR 
Brett Maas, Managing Partner 
Phone: (646) 536-7331 
Email: brett@haydenir.com 
www.haydenir.com

AIkido Pharma Inc. 
Phone: 212-745-1373 
Email: investorrelations@aikidopharma.com 
www.aikidopharma.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/aikido-pharma-inc-appoints-new-director-soo-yu-301566023.html

SOURCE AIkido Pharma Inc.

FAQ

What is the significance of Soo Yu's appointment to AIkido Pharma Inc.?

Soo Yu's appointment is significant as it addresses shareholder concerns about diversity compliance with NASDAQ rules and brings valuable international business expertise to the board.

How does Soo Yu's background contribute to AIkido Pharma's growth?

Soo Yu's experience in international business development, particularly in Asian markets, can help AIkido explore new growth opportunities and enhance its global presence.

When was Soo Yu appointed as a director of AIkido Pharma Inc.?

Soo Yu was appointed as a director on June 10, 2022.

What are the potential impacts of the new director on AIkido Pharma's operations?

The appointment of Soo Yu could positively impact AIkido's operations by diversifying the board's expertise and possibly leading to new strategic partnerships and market opportunities.